Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes

Kidney International

Volumn 75, Issue 9, 2009, Pages 961-968

  Brunelli, Steven M ^a,b,e   Thadhani, Ravi ^c   Ikizler, T Alp ^d   Feldman, Harold I ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Diabetes; Dialysis; Epidemiology; Mortality; Survival thiazolidinediones

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE; GLITAZONE DERIVATIVE; INSULIN; MEGLITINIDE; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG USE; FEMALE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME;

COHORT STUDIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 64949086377     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.4     Document Type: Article

References (45)

1. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, U.S. Renal Data System, USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. http://www.usrds.org/ Accessed May 17, 2008, Bethesda, MD.
2. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32(Suppl 3): S112-S119.
3. Kalantar-Zadeh K, Kilpatrick RD, Kuwae N et al Revisiting mortality predictability of serum albumin in the dialysis population: time dependency, longitudinal changes and population-attributable fraction Nephrol Dial Transplant 2005; 20 1880-1888.
4. de Mutsert R, Grootendorst DC, Axelsson J et al Excess mortality due to interaction between protein-energy wasting, inflammation and cardiovascular disease in chronic dialysis patients Nephrol Dial Transplant 2008; 23 2957-2964.
5. Pupim LB, Flakoll PJ, Majchrzak KM et al Increased muscle protein breakdown in chronic hemodialysis patients with type 2 diabetes mellitus Kidney Int 2005; 68 1857-1865.
6. Pupim LB, Heimburger O, Qureshi AR et al Accelerated lean body mass loss in incident chronic dialysis patients with diabetes mellitus Kidney Int 2005; 68 2368-2374.
7. Yki-Jarvinen H Thiazolidinediones N Engl J Med 2004; 351 1106-1118.
8. Lebovitz HE, Dole JF, Patwardhan R et al Rosiglitazone monotherapy is effective in patients with type 2 diabetes J Clin Endocrinol Metab 2001; 86 280-288.
9. Fonseca V, Rosenstock J, Patwardhan R et al Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial JAMA 2000; 283 1695-1702.
10. Gomez-Perez FJ, Fanghanel-Salmon G, Antonio Barbosa J et al Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes Diabetes Metab Res Rev 2002; 18 127-134.
11. Vongthavaravat V, Wajchenberg BL, Waitman JN et al An international study of the effects of rosiglitazone plus sulphonylurea in patients with type 2 diabetes Curr Med Res Opin 2002; 18 456-461.
12. Raskin P, Rendell M, Riddle MC et al A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes Diabetes Care 2001; 24 1226-1232.
13. Aronoff S, Rosenblatt S, Braithwaite S et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled doseresponse study The Pioglitazone 001 Study Group Diabetes Care 2000; 23 1605-1611.
14. Rosenblatt S, Miskin B, Glazer NB et al The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus Coron Artery Dis 2001; 12 413-423.
15. Einhorn D, Rendell M, Rosenzweig J et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study The Pioglitazone 027 Study Group Clin Ther 2000; 22 1395-1409.
16. Kipnes MS, Krosnick A, Rendell MS et al Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study Am J Med 2001; 111 10-17.
17. Rosenstock J, Einhorn D, Hershon K et al Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy Int J Clin Pract 2002; 56 251-257.
18. Miyazaki Y, Mahankali A, Matsuda M et al Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients J Clin Endocrinol Metab 2002; 87 2784-2791.
19. Haffner SM, Greenberg AS, Weston WM et al Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus Circulation 2002; 106 679-684.
20. Marx N, Froehlich J, Siam L et al Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease Arterioscler Thromb Vasc Biol 2003; 23 283-288.
21. Caballero AE, Saouaf R, Lim SC et al The effects of troglitazone, an insulinsensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial Metabolism 2003; 52 173-180.
22. Sidhu JS, Kaposzta Z, Markus HS et al Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus Arterioscler Thromb Vasc Biol 2004; 24 930-934.
23. Mazzone T, Meyer PM, Feinstein SB et al Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial Jama 2006; 296 2572-2581.
24. Wang X, Hu Z, Hu J et al Insulin resistance accelerates muscle protein degradation: Activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling Endocrinology 2006; 147 4160-4168.
25. Schneider CA, Ferrannini E, Defronzo R et al Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease J Am Soc Nephrol 2008; 19 182-187.
26. Teng M, Wolf M, Ofsthun MN et al Activated injectable vitamin D and hemodialysis survival: a historical cohort study J Am Soc Nephrol 2005; 16 1115-1125.
27. Longenecker JC, Coresh J, Powe NR et al Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study J Am Soc Nephrol 2002; 13 1918-1927.
28. Krane V, Drechsler C, Wanner C Dyslipidemia, inflammation and dialysis outcomes: what we know now Curr Opin Nephrol Hypertens 2006; 15 566-570.
29. Pifer TB, McCullough KP, Port FK et al Mortality risk in hemodialysis patients and changes in nutritional indicators: DOPPS Kidney Int 2002; 62 2238-2245.
30. Gutierrez A, Alvestrand A, Wahren J et al Effect of in vivo contact between blood and dialysis membranes on protein catabolism in humans Kidney Int 1990; 38 487-494.
31. Caglar K, Peng Y, Pupim LB et al Inflammatory signals associated with hemodialysis Kidney Int 2002; 62 1408-1416.
32. Ikizler TA, Flakoll PJ, Parker RA et al Amino acid and albumin losses during hemodialysis Kidney Int 1994; 46 830-837.
33. Kalantar-Zadeh K, Block G, McAllister CJ et al Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients Am J Clin Nutr 2004; 80 299-307.
34. Khan MA, St Peter JV, Xue JL A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone Diabetes Care 2002; 25 708-711.
35. Singh S, Loke YK, Furberg CD Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis JAMA 2007; 298 1189-1195.
36. Nissen SE, Wolski K Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 2007; 356 2457-2471.
37. Dahabreh IJ Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone Clin Trials 2008; 5 116-120.
38. Kahn SE, Haffner SM, Heise MA et al Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N Engl J Med 2006; 355 2427-2443.
39. Nakamura T, Ushiyama C, Osada S et al Effect of pioglitazone on dyslipidemia in hemodialysis patients with type 2 diabetes Ren Fail 2001; 23 863-864.
40. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 1998; 352 837-853.
41. Ansari A, Thomas S, Goldsmith D Assessing glycemic control in patients with diabetes and end-stage renal failure Am J Kidney Dis 2003; 41 523-531.
42. Ritz E, Dikow R, Adamzcak M et al Congestive heart failure due to systolic dysfunction: the Cinderella of cardiovascular management in dialysis patients Semin Dial 2002; 15 135-140.
43. Efrati S, Zaidenstein R, Dishy V et al ACE inhibitors and survival of hemodialysis patients Am J Kidney Dis 2002; 40 1023-1029.
44. Takahashi A, Takase H, Toriyama T et al Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis-a randomized study Nephrol Dial Transplant 2006; 21 2507-2512.
45. Lunn M, McNeil D Applying Cox regression to competing risks Biometrics 1995; 51 524-532.